Zai Lab (ZLAB) Panoramica del titolo
Zai Lab Limited, un'azienda biofarmaceutica, si concentra sulla scoperta, lo sviluppo e la commercializzazione di prodotti che affrontano condizioni mediche nelle aree dell'oncologia, dell'immunologia, delle neuroscienze e delle malattie infettive. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 3/6 |
| Crescita futura | 2/6 |
| Prestazioni passate | 0/6 |
| Salute finanziaria | 4/6 |
| Dividendi | 0/6 |
ZLAB Community Fair Values
Create NarrativeSee what 18 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di Zai Lab Limited
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | US$20.44 |
| Massimo di 52 settimane | US$41.20 |
| Minimo di 52 settimane | US$15.96 |
| Beta | 0.76 |
| Variazione di 1 mese | 15.28% |
| Variazione a 3 mesi | -13.02% |
| Variazione di 1 anno | -42.37% |
| Variazione a 3 anni | -29.15% |
| Variazione a 5 anni | -86.91% |
| Variazione dall'IPO | 13.56% |
Notizie e aggiornamenti recenti
Aggiornamento narrativa • Jun 18
ZLAB: DLL3 Program And China Approval Will Drive Long-Term Upside
The analyst price target for Zai Lab has been adjusted slightly lower to $33.30 from $33.78, with analysts citing incremental updates to fair value estimates, the discount rate, revenue growth, profit margin, and future P/E assumptions. What’s in the News for Zai Lab Zai Lab received approval from China’s National Medical Products Administration for TIVDAK to treat adult patients with recurrent or metastatic cervical cancer whose disease progressed after chemotherapy, supported by overall survival data from the Phase 3 innovaTV 301 trial (primary news, NMPA filing).Articolo di analisi • Jun 16
Zai Lab (ZLAB) Stock Could Be 47.5% Undervalued After China Approved TIVDAK
Zai Lab (ZLAB) stock is in focus after China’s National Medical Products Administration approved TIVDAK for adults with recurrent or metastatic cervical cancer whose disease progressed on or after chemotherapy. See our latest analysis for Zai Lab. The NMPA approval for TIVDAK comes after a mixed stretch for Zai Lab, with the stock showing a 1-day share price return of 3.87% and a 7-day share price return of 7.58%, yet a 1-year total shareholder return that declined 56.36%. This suggests...Recent updates
Aggiornamento narrativa • Jun 18
ZLAB: DLL3 Program And China Approval Will Drive Long-Term Upside
The analyst price target for Zai Lab has been adjusted slightly lower to $33.30 from $33.78, with analysts citing incremental updates to fair value estimates, the discount rate, revenue growth, profit margin, and future P/E assumptions. What’s in the News for Zai Lab Zai Lab received approval from China’s National Medical Products Administration for TIVDAK to treat adult patients with recurrent or metastatic cervical cancer whose disease progressed after chemotherapy, supported by overall survival data from the Phase 3 innovaTV 301 trial (primary news, NMPA filing).Articolo di analisi • Jun 16
Zai Lab (ZLAB) Stock Could Be 47.5% Undervalued After China Approved TIVDAK
Zai Lab (ZLAB) stock is in focus after China’s National Medical Products Administration approved TIVDAK for adults with recurrent or metastatic cervical cancer whose disease progressed on or after chemotherapy. See our latest analysis for Zai Lab. The NMPA approval for TIVDAK comes after a mixed stretch for Zai Lab, with the stock showing a 1-day share price return of 3.87% and a 7-day share price return of 7.58%, yet a 1-year total shareholder return that declined 56.36%. This suggests...Aggiornamento narrativa • Jun 03
ZLAB: DLL3 Combinations And Fast Track Designation Will Support Long-Term Expansion
Analysts have reduced their price target on Zai Lab by $7, reflecting updated views on fair value, discount rates, growth assumptions, margins, and future P/E expectations following recent research. What's in the News President and COO Josh Smiley plans to leave Zai Lab effective May 22, 2026, as part of a broader leadership reshuffle related to operational efficiency efforts and preparations for the launch of COBENFY in China and several oncology data readouts in 2026, according to recent company announcements.Seeking Alpha • May 13
Zai Lab: A Speculative Bet On Global Oncology, With A Greater China Bag Attached
Summary Zai Lab faces stalling growth in Greater China due to price controls and declining Zejula revenues, shifting focus to global pipeline assets. I assign zero intrinsic value to ZLAB's China business, given minimal "bottom line" contributions from blockbuster launches like Vyvgart and anticipated similar outcomes for KarXT. Zoci, a wholly owned Phase 3 oncology asset, is the key value driver for the company, with a modeled global rNPV near $1 billion and potential for multi-billion upside if expanded to 1L SCLC. I maintain a Speculative Buy rating on ZLAB, as its valuation hinges almost entirely on Zoci's clinical and commercial success, with risks from cash burn and competition. Read the full article on Seeking AlphaArticolo di analisi • May 11
Zai Lab Limited (NASDAQ:ZLAB) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
It's been a sad week for Zai Lab Limited ( NASDAQ:ZLAB ), who've watched their investment drop 12% to US$18.60 in the...Aggiornamento narrativa • May 01
ZLAB: Diversified Pipeline And DLL3 Partnerships Will Support Long-Term Expansion
The analyst price target for Zai Lab has been reduced by about $14 to $35, with analysts citing lower modeled revenue growth, modestly higher discount rates, and management's commentary on more modest 2026 top line expectations given pricing pressures and competition in China. Analyst Commentary Recent Street research on Zai Lab points to a more cautious stance on revenue growth and valuation, with several firms trimming their price targets while still recognizing areas of execution strength and pipeline potential.
Aggiornamento narrativa • Apr 16
ZLAB: Cautious China Outlook And Pipeline Progress Will Shape A Measured Re Rating
Analysts have lowered their average price targets on Zai Lab by several dollars, citing more cautious expectations for 2026 revenue growth. Management anticipates modest top line trends with pricing pressure and rising competition in China, which is reflected in slightly adjusted P/E assumptions and growth inputs.Aggiornamento narrativa • Apr 02
ZLAB: Mixed Coverage And Pipeline Progress Will Shape A Measured Re Rating
Analysts have trimmed their price targets on Zai Lab, and the model update now points to a fair value of $21.80. This reflects expectations for more modest revenue growth and profit margins, along with a higher future P/E multiple.
Aggiornamento narrativa • Mar 19
ZLAB: China Approvals And Oncology Pipeline Progress Will Support Future Upside Potential
Analysts have trimmed their price targets on Zai Lab by up to $18, reflecting more cautious assumptions on revenue growth and competitive pressures. At the same time, updated models incorporate a higher projected profit margin and a lower future P/E multiple.Aggiornamento narrativa • Mar 04
ZLAB: China Approvals And Pipeline Execution Will Support Future Upside Potential
Narrative Update The updated analyst price target for Zai Lab has moved down from $67.22 to $55.00 as analysts factor in more modest projected revenue growth, lower profit margins, a higher assumed discount rate, and recent Street research pointing to pricing pressure, competition in China, and adjustments to company models following management commentary. Analyst Commentary Recent Street research on Zai Lab shows a mix of recalibrated price targets and ongoing constructive views on execution and longer term growth prospects.Aggiornamento narrativa • Feb 17
ZLAB: Mixed Coverage And New Approvals Will Shape A Measured Re Rating
Analysts trimmed their price targets on Zai Lab by $3.03, reflecting updated fair value and P/E assumptions, as well as fresh views on the company following recent research coverage changes. Analyst Commentary Recent Street research on Zai Lab has sent a mixed message, with some optimism around longer term potential but also fresh caution on how the current share price lines up with execution risks and valuation assumptions.Aggiornamento narrativa • Feb 03
ZLAB: Fresh Coverage And Pipeline Progress Will Support A Re Rating
The updated analyst price target for Zai Lab moves to about US$23.45 from about US$28.14, as analysts factor in lower revenue growth assumptions and a lower future P/E multiple, partly offset by higher projected profit margins and supported by fresh coverage and a US$35 target from recent Street research. Analyst Commentary While the updated blended price target for Zai Lab sits around US$23.45, investor sentiment is being pulled in different directions.Aggiornamento narrativa • Jan 20
ZLAB: Pipeline And New China Approvals Will Drive Future Upside Potential
Analysts have nudged their fair value estimate for Zai Lab to US$67.22 per share, reflecting slightly updated assumptions on discount rate, revenue growth, profit margin, and future P/E following fresh coverage initiation and list changes in recent Street research. Analyst Commentary Street research on Zai Lab has been mixed recently, but the latest fair value update and fresh coverage suggest that some bullish analysts still see room for upside relative to current pricing.Aggiornamento narrativa • Jan 06
ZLAB: Pipeline Execution After Conviction List Removal Will Drive Upside Potential
Analysts have trimmed their fair value estimate for Zai Lab from US$74.00 to US$67.22, citing updated assumptions for discount rates, revenue growth, profit margins and future P/E multiples following its removal from a regional conviction list by a major broker. Analyst Commentary Goldman Sachs removed Zai Lab from its APAC Conviction List as part of a broader monthly review, which has prompted some investors to reassess expectations and risk appetite around the stock.Aggiornamento narrativa • Dec 20
ZLAB Removed From Conviction List Yet Future Pipeline Progress May Re-Rate Shares
Analysts have cut their price target on Zai Lab from approximately $39 to about $28, reflecting a materially lower growth outlook and higher perceived risk, as evidenced by its recent removal from a major APAC conviction list. Analyst Commentary Bearish analysts have interpreted the removal of Zai Lab from a major APAC conviction list as a signal that the company may face a more challenging path to justifying a premium valuation, particularly given rising competition and execution uncertainties in its pipeline and commercialization strategy.Aggiornamento narrativa • Dec 06
ZLAB: Diversified Pipeline Is Expected To Drive Long-Term Market Expansion
Narrative Update on Zai Lab Analysts have moderately lowered their price target on Zai Lab to approximately $49.49, reflecting more conservative assumptions for revenue growth and profit margins, along with the stock’s recent removal from a key regional conviction list. Analyst Commentary Recent research updates on Zai Lab have prompted a more nuanced view of the company’s risk and reward profile, with analysts highlighting both supportive fundamentals and execution challenges that could influence the stock’s re-rating trajectory.Aggiornamento narrativa • Nov 22
ZLAB: Pipeline Diversification And Ongoing Partnerships Will Support Long-Term Market Expansion
Zai Lab's analyst price target has been revised downward from approximately $53.40 to $49.49. Analysts cite concerns over slowing revenue growth and narrowing profit margins.Articolo di analisi • Nov 09
Zai Lab Limited (NASDAQ:ZLAB) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Zai Lab Limited ( NASDAQ:ZLAB ) missed earnings with its latest third-quarter results, disappointing overly-optimistic...Articolo di analisi • Nov 07
Analyst Forecasts Just Became More Bearish On Zai Lab Limited (NASDAQ:ZLAB)
Market forces rained on the parade of Zai Lab Limited ( NASDAQ:ZLAB ) shareholders today, when the analysts downgraded...Aggiornamento narrativa • Nov 07
ZLAB: Future Product Launches Will Drive Broader Market Reach And Patient Access
Analysts have lowered their price target for Zai Lab from approximately $55.41 to $53.40. They cite adjustments in key financial projections and the company's recent removal from a major conviction list as supporting factors.Articolo di analisi • Nov 06
Revenues Working Against Zai Lab Limited's (NASDAQ:ZLAB) Share Price Following 26% Dive
Zai Lab Limited ( NASDAQ:ZLAB ) shareholders that were waiting for something to happen have been dealt a blow with a...Articolo di analisi • Oct 05
Is Zai Lab (NASDAQ:ZLAB) Using Debt Sensibly?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Aggiornamento narrativa • Sep 23
Expanding China Healthcare And Global Pipelines Will Broaden Patient Options
Despite encouraging Phase III trial data for bemarituzumab in gastric cancer, which bolsters near-term commercial outlooks and regulatory momentum in China, Zai Lab’s consensus analyst price target saw only a slight downward adjustment from $56.31 to $55.41. Analyst Commentary Positive Phase III FORTITUDE-101 trial data for bemarituzumab in first-line FGFR2b+ gastric cancer.Articolo di analisi • Jun 16
Revenues Not Telling The Story For Zai Lab Limited (NASDAQ:ZLAB) After Shares Rise 33%
Zai Lab Limited ( NASDAQ:ZLAB ) shares have had a really impressive month, gaining 33% after a shaky period beforehand...
Nuova narrativa • Apr 30
New VYVGART And Pipeline Advances Will Expand Global Markets
Strong revenue growth is expected due to robust product launches and pipeline innovations, with profitability anticipated through cost optimization and operational efficiencies.Seeking Alpha • Mar 20
Zai Lab: Still Attractive Despite Higher Costs And Added Trade War Risks
Summary ZLAB’s Vyvgart revenue has been impressive, rising from roughly $93.6 million in 2024. I now consider this IP one of ZLAB’s main growth drivers. ZLAB’s ongoing strategy of focusing on Chinese approvals continues to pay off with Vyvgart Hytrulo, Xacduro, and Augtyro in oncology and autoimmune diseases. They also have late-stage assets like Bemarituzumab (gastric cancer), KarXT (schizophrenia), and Optune (pancreatic/lung cancer) that could become major revenue verticals in China. ZLAB’s balance sheet is pretty solid, with close to 2.4 years of runway, and aiming towards profitability by yearend 2025. ZLAB’s valuation is higher than when I first covered it. New trade risks between the US and China also exist, but I remain bullish at these levels. Read the full article on Seeking AlphaArticolo di analisi • Mar 06
Zai Lab Limited's (NASDAQ:ZLAB) 31% Share Price Surge Not Quite Adding Up
Zai Lab Limited ( NASDAQ:ZLAB ) shareholders have had their patience rewarded with a 31% share price jump in the last...Articolo di analisi • Jan 20
Investors Don't See Light At End Of Zai Lab Limited's (NASDAQ:ZLAB) Tunnel
You may think that with a price-to-sales (or "P/S") ratio of 7.9x Zai Lab Limited ( NASDAQ:ZLAB ) is a stock worth...Seeking Alpha • Dec 26
Zai Lab: Rapidly Improving Outlook Bodes Well For The Future
Summary Zai Lab Limited is transitioning from a "Hold" to a "Buy" rating due to rapid revenue growth and upcoming potential approvals. ZLAB's strategy involves in-licensing U.S.-approved drugs for the Chinese market, with key products like Zejula, Qinlock, Nuzyra, Vyvgart, and Optune driving revenue. Despite high costs, ZLAB's consistent quarterly revenue growth and a strong cash position indicate a promising future. Zai Lab's unique market position and strong pipeline make it a compelling investment for those with high risk tolerance. Read the full article on Seeking AlphaArticolo di analisi • Nov 15
The Zai Lab Limited (NASDAQ:ZLAB) Third-Quarter Results Are Out And Analysts Have Published New Forecasts
There's been a notable change in appetite for Zai Lab Limited ( NASDAQ:ZLAB ) shares in the week since its...Articolo di analisi • Sep 28
Zai Lab Limited (NASDAQ:ZLAB) Stock Catapults 26% Though Its Price And Business Still Lag The Industry
Zai Lab Limited ( NASDAQ:ZLAB ) shares have continued their recent momentum with a 26% gain in the last month alone...Articolo di analisi • Sep 23
Zai Lab (NASDAQ:ZLAB) Has Debt But No Earnings; Should You Worry?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Articolo di analisi • Jun 12
Shareholders May Not Be So Generous With Zai Lab Limited's (NASDAQ:ZLAB) CEO Compensation And Here's Why
Key Insights Zai Lab will host its Annual General Meeting on 18th of June Salary of US$868.5k is part of CEO Samantha...Articolo di analisi • May 14
Improved Revenues Required Before Zai Lab Limited (NASDAQ:ZLAB) Stock's 50% Jump Looks Justified
Zai Lab Limited ( NASDAQ:ZLAB ) shareholders would be excited to see that the share price has had a great month...Seeking Alpha • Apr 16
A Risky Bet: Zai Lab's Uncertain Future
Summary Zai Lab offers a weaker value proposition for investors looking to bet on Chinese biotech due to its pure license in approach, limiting its potential to tap into global market. Its key products have shown a slow-down in 2023 and is facing increased competition. There is limited excitement in the current pipeline, as competitors have already taken the lead in the development timeline. The company is overvalued because it is trading at a similar P/S ratio to its peers, even though it has weaker quality in several key aspects. Read the full article on Seeking AlphaRendimenti per gli azionisti
| ZLAB | US Biotechs | US Mercato | |
|---|---|---|---|
| 7D | 3.5% | -3.5% | 0.8% |
| 1Y | -42.4% | 32.8% | 20.5% |
Ritorno vs Industria: ZLAB ha avuto una performance inferiore rispetto al US Biotechs che ha registrato un rendimento 32.8 % nell'ultimo anno.
Rendimento vs Mercato: ZLAB ha avuto una performance inferiore al mercato US che ha registrato un rendimento 20.5 % nell'ultimo anno.
Volatilità dei prezzi
| ZLAB volatility | |
|---|---|
| ZLAB Average Weekly Movement | 7.1% |
| Biotechs Industry Average Movement | 10.2% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.2% |
Prezzo delle azioni stabile: ZLAB non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato US.
Volatilità nel tempo: La volatilità settimanale ( 7% ) di ZLAB è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 2013 | 1,784 | Samantha Du | www.zailaboratory.com |
Zai Lab Limited, una società biofarmaceutica, si concentra sulla scoperta, lo sviluppo e la commercializzazione di prodotti che affrontano condizioni mediche nelle aree dell'oncologia, dell'immunologia, delle neuroscienze e delle malattie infettive. I suoi prodotti commerciali includono Zejula, un inibitore della poli (ADP-ribosio) polimerasi 1/2 somministrato per via orale per il trattamento del cancro alle ovaie; VYVGART, un frammento di anticorpo IgG1 umano per la miastenia gravis generalizzata e la polineuropatia demielinizzante infiammatoria cronica; NUZYRA per la polmonite batterica acquisita in comunità e le infezioni batteriche acute della pelle e delle strutture cutanee; Optune per il glioblastoma multiforme; Qinlock per i tumori stromali gastrointestinali; Xacduro per il trattamento della polmonite batterica nosocomiale e associata a ventilazione causata da un complesso cinetobacter baumannii-calcoaceticus; e Augtyro per il trattamento del proto-oncogene 1 ROS e del carcinoma polmonare non a piccole cellule. L'azienda ha una collaborazione strategica con Tesaro, Inc., NovoCure Ltd., Deciphera Pharmaceuticals, LLC, Paratek Bermuda Ltd., argent BV, Turning Point Therapeutics, Inc., Entasis Therapeutics Holdings Inc., Karuna Therapeutics, Inc., Pfizer Inc., Amgen Inc. e con Boehringer Ingelheim GmbH.
Zai Lab Limited Riepilogo dei fondamenti
| ZLAB statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | US$2.17b |
| Utili (TTM) | -US$178.11m |
| Ricavi(TTM) | US$453.28m |
5.1x
Rapporto P/S-12.9x
Rapporto P/EZLAB è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| ZLAB Conto economico (TTM) | |
|---|---|
| Ricavi | US$453.28m |
| Costo del fatturato | US$416.54m |
| Profitto lordo | US$36.75m |
| Altre spese | US$214.86m |
| Utili | -US$178.11m |
Ultimi utili riportati
Mar 31, 2026
Prossima data di guadagno
n/a
| Utile per azione (EPS) | -1.59 |
| Margine lordo | 8.11% |
| Margine di profitto netto | -39.29% |
| Rapporto debito/patrimonio netto | 32.3% |
Come si è comportato ZLAB nel lungo periodo?
Vedi performance storica e confrontoAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/07/15 04:20 |
| Prezzo dell'azione a fine giornata | 2026/07/15 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Zai Lab Limited è coperta da 33 analisti. 16 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Rebecca Liang | Bernstein |
| Bo Li | BofA Global Research |
| Louise Chen | Cantor Fitzgerald & Co. |